Nocturnal asthma is potentially dangerous' 2 and may be difficult to treat. Slow release oral preparations of methylxanthines3 or high dose aerosol treatment with /2 stimulants4 have been advocated. In our experience, however, both of these groups of drugs may be quite ineffective in some patients and many patients cannot tolerate methylxanthines in effective doses. The dose of sympathomimetic drugs may be more important than the route of administration. Accepted I April 1985 ments were given under double blind crossover conditions with randomised treatment order. Treatments were changed every two weeks, when the investigator also reviewed symptoms by a questionnaire and measured forced expiratory volume in one second (FEVy) and forced vital capacity (FVC). In weeks 3 and 4, patients took nebulised sodium cromoglycate 20 mg (2 ml of 1% cromoglycate nebuliser solution), using a Wright nebuliser and electric compressor, on waking, at 1800, and at bedtime and 20 mg by dry powder aerosol from a spinhaler at 1200, or placebo nebuliser solution and capsules. In weeks 4 and 5 they took 80 mg sodium cromoglycate by nebulisation (4 ml of a 2% cromoglycate solution) three times a day and 40 mg by dry powder inhalation at 1200, or corresponding placebos. Weeks 6 and 7 comprised a washout period when sympathomimetic drugs were continued without any trial medication. In weeks 7 and 8 and weeks 9 and 10 patients crossed over to low and high dose regimens of sodium cromoglycate or placebo, depending on the previous randomisation for active or placebo treatment.
xanthines3 or high dose aerosol treatment with /2 stimulants4 have been advocated. In our experience, however, both of these groups of drugs may be quite ineffective in some patients and many patients cannot tolerate methylxanthines in effective doses. The dose of sympathomimetic drugs may be more important than the route of administration. 5 The mechanisms underlying nocturnal asthma are poorly understood. 6 The most widely accepted view is that it results from the permissive effect on release of mediators from mast cells at night as circulating catecholamine concentrations fall.7 Sodium cromoglycate might therefore be expected to control nocturnal asthma by stabilising mast cells. Moreover, its low toxicity might facilitate the use of proportionally higher doses than can be contemplated with sympathomimetic drugs. We have studied the effects of sodium cromoglycate, in a standard dosage of 80 mg/day and a high dosage of 280 mg/day, versus placebo in patients with nocturnal asthma that was inadequately controlled by sympathomimetic drugs.
Methods
Patients were recruited who had nocturnal or early morning wheezing on at least three days a week and who showed an early morning fall in peak expiratory flow rate ( tBreathlessness scored on scale 0-3. §Mean number of extra puffs per day (or night).
Discussion
Benefits from treatment with sodium cromoglycate were small in these patients who were already having regular treatment with sympathomimetic drugs. There was no evidence of improvement in the overnight fall in PEFR but some symptomatic benefit in terms of frequency of nocturnal wheezing and bronchodilator aerosol consumption was seen. There was no evidence of any greater efficacy for the high dose regimen. This may simply mean that sodium cromoglycate is an inappropriate treatment for nocturnal asthma irrespective of dose. It is difficult to nebulise this large dose, however, and patients remarked that inhalation from the nebuliser was time consuming. Thus inhalation of the higher dose may have been incomplete. Use of a larger number of powder aerosol capsules might therefore have been more efficient. An inpatient study of 160 mg sodium cromoglycate by nebulisation in nocturnal asthma at bedtime8 showed small improvements over placebo for overnight fall in vital capacity and oxygen saturation but not FEV,. There was also less sleep disturbance. A comparison of sodium cromoglycate with ketotifen9 included data on overnight fall in PEFR and showed a very small benefit from cromoglycate by comparison with placebo.
The lack of an appreciable benefit from standard or high doses of sodium cromoglycate in the control of nocturnal asthma does not therefore support the hypothesis that nocturnal release of mediators from mast cells causes nocturnal asthma7-with the caveat that the inhibition of mast cell degranulation by cromoglycate that is demonstrable in animal models may not fully account for its clinical effectiveness in asthma.'0 Although sympathomimetic drugs may inhibit mediator release from mast cells, their beneficial effects in nocturnal asthma34 could be explained by their direct action on bronchial smooth muscle alone.
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